Effect of Excipients on the Stability and Aerosol Performance of Nebulized Aviscumine

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 16, Issue 4, 2003, Pages 417-432

  Steckel, Hartwig ^a,c   Eskandar, Fadi ^a   Witthohn, Klaus ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b VISCUM AG   (Germany)

^c Dept of Pharmaceut/Biopharmaceut ^*  (Germany)

Author keywords

Aviscumine; Buffer salts; Nebulization; Octanoyl N methylglucamide; Stability of proteins; Tricine

Indexed keywords

AVISCUMINE; EDETATE DISODIUM; EXCIPIENT; HETASTARCH; POLYSORBATE; TROMETAMOL; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT;

ARTICLE; BINDING ASSAY; DRUG ACTIVITY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; FREEZE DRYING; METERED DOSE INHALER; NEBULIZATION; NEBULIZER; PERFORMANCE;

ADMINISTRATION, INHALATION; AEROSOLS; BIOLOGICAL AVAILABILITY; DRUG STABILITY; EQUIPMENT DESIGN; EQUIPMENT SAFETY; EXCIPIENTS; HUMANS; MODELS, THEORETICAL; NEBULIZERS AND VAPORIZERS; OCTANOLS; PLANT PREPARATIONS; PLANT PROTEINS; SENSITIVITY AND SPECIFICITY; SURFACE PROPERTIES; TOXINS, BIOLOGICAL;

EID: 1642433360     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/089426803772455677     Document Type: Article

References (38)

1. Bocci, V. 1993. Mistletoe (Viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy. J. Biol. Reg. Homeos. Agents 7:1-6.
2. Eck, J., Langer, M., Möckel, B., et al. 1999a. Cloning of the mistletoe lectin gene and characterization of the recombinant A-chain. Eur. J. Biochem. 264:775-784.
3. Eck, J., Langer, M., Möckel, B., et al. 1999b. Characteristics of recombinant and plant-derived mistletoe lectin and their chain. Eur. J. Biochem. 264:944-948.
4. Schumacher, U., Feldhaus, S., and Mengs, U. 2000. Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice. Cancer Lett. 150:171-175.
5. Witthohn, K., Möckel, B., Hausmann, I., et al. 2002. Preformulation studies with the thermodynamic protein aviscumine as prerequisite for clinical trials. Presented at the 4th World Meeting ADRITELF/APGI/APV, Florence.
6. Gloger, O., Witthohn, K., and Müller, B.W. 2002. Stabilization of aviscumine during freeze-drying by different polysaccharides. Presented at the 4th World Meeting ADRITELF/APGI/APV, Florence.
7. Effros, R.M. 1996. Solute transport following aerosol deposition in the lungs. In A.J. Hickey, ed. Inhalation Aerosols, Vol. 94. Marcel Dekker, New York, 139-154.
8. Gupta, P., and Adjei, A. 1997. Therapeutic inhalation aerosols. In A. Adjei and P. Gupta, eds. Inhalation Delivery of Therapeutic Peptides and Proteins. Marcel Dekker, New York, 185-234.
9. Ip, A., Arakawa, T., Silvers, H., et al. 1995. Stability of recombinant consensus interferon to air-jet and ultrasonic nebulization. J. Pharm. Sci. 84:1210-1214.
10. Gloger, O. 2002. Stabilisierung von rekombinantem Mistellektin durch Gefriertrocknung [Doctoral dissertation]. Christian Albrecht University, Kiel, Germany.
11. Gloger, O., and Müller, B.W. 2000. Influence of freezing on the pH-shift of different buffer systems. Presented at the 3rd World Meeting APV/APGI, Berlin.
12. Chang, B.S., Kendrick, B.S., and Carpenter, J.F. 1996. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J. Pharm. Sci. 12:1325-1330.
13. Webb, S.D., Cleland, J.L., Carpenter, J.F., et al. 2002. A new mechanism for decreasing aggregation of recombinant human interferon-γ by a surfactant. Int. J. Pharm. 91:543-558.
14. Woog, H. 1993. Lyophilisation. Stabilisierung von Wirkstoffen durch Gefriertrocknung: Lyophilisation aus nicht wäflrigen Lösungen sowie Optimierung von Gefriertrockntmgsprozessen. In D. Essig, and R. Oschmann, eds. Lyophilisation, Vol. 35. VWG, Stuttgart, 39-60.
15. Lee, J., and Timasheff, S. 1981. The stabilization of proteins by sucrose. J. Biol. Chem. 256:7193-7201.
16. Timasheff, S. 1992. Stabilization of protein structure by solvent additives. Pharm. Biotechnol. 3:265-285.
17. Cipolla, D.D., Clark, A.R., Chan, H.K., et al. 1994. Assessment of aerosol delivery system for recombinant human desoxyribonuclease. S.T.P. Pharma 4:50-62.
18. Sethuraman, V., and Hickey, A. 2002. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. PharmSciTech. 3:28.
19. Arakawa, T., Prestreliski, S.J., Kenney, W.C., et al. 1993. Factors affecting short-term and long-term stability of protein. Adv. Drug Deliv. 10:1-28.
20. Arakawa, T., and Timasheff, S.N. 1982. Preferential interaction of proteins with salts in concentrated solutions. Biochemistry 21:6545-6557.
21. Lin, T., and Timasheff, S.N. 1996. On the role of surface tension in the stabilization of globular proteins. Protein Sci. 5:372-381.
22. Niven, R. 1997. Feasibility studies with recombinant human granulocyte colony-stimulating factor. In A. Adjei and P. Gupta, eds. Inhalation Delivery of Therapeutic Peptides and Proteins. Marcel Dekker, New York, 413-452.
23. Townsend, M., Byron, P., and DeLuca, P. 1990. The effects of formulation additives on the degradation of freeze-dried ribonuclease A. Pharm. Res. 7:1086-1091.
24. Conway, S.P., and Watson, A. 1997. Nebulized bronchodilators, corticosteroids and rhDNase in adult patients with cystic fibrosis. Thorax 52:64-68.
25. Niven, R.W., Ip, A.Y., Mittelman, S., et al. 1995. Some factors associated with the ultrasonic nebulization of proteins. Pharm. Res. 12:53-59.
26. Mercer, T.T., Goddard, B.F., and Flores, R.L. 1968. Output characteristics of three ultrasonic nebulizers. Ann. Allergy 26:18-27.
27. Sato, Y., Sato, M., Kita, M., et al. 1992. Comparison of 80 kHz and 160 kHz ultrasonic aerosolization of interferon-alpha. J. Aerosol Med. 5:59-64.
28. Steckel, H., Eskandar, F., and Witthohn, K. 2003. The effect of formulation variables on the stability of nebulized aviscumine. Int. J. Pharm. 257:181-194.
29. Zhang, M.Z., Wen, J., Arakawa, T., et al. 1995. A new strategy for enhancing the stability of lyophilized proteins: the effect of the reconstitution medium on keratinocyte growth factor. Pharm. Res. 12:1447-1451.
30. Hildreth, J.E. 1982. N-D-Gluco-N-methylalkanamide compounds, a new class of non-ionic detergents for membrane biochemistry. Biochemistry 207:363-366.
31. Lalor, C.B., and Hickey, A.J. 1997. Generation and characterization of aerosols for drug delivery to the lungs. In A.L. Adjei and P.K. Gupta, eds. Inhalation Delivery of Therapeutic Peptides and Proteins. Marcel Dekker, New York, 235-276.
32. Davis, S.S. 1978. Physico-chemical studies on aerosol solutions for drug delivery. Int. J. Pharm. 1:71-83.
33. Newman, S.P., Pellow, P.G., and Clarke, S.W. 1987. Droplets sizes from medical atomizers (nebulizers) for drug solutions of different viscosity and surface tension. Atomization Spray Tech. 3:1-11.
34. Callaghan, C.O., and Barry, P.W. (1997). The science of nebulized drug delivery. Thorax 52:31-44.
35. Mercer, T.T. 1981. Production of therapeutic aerosols: principles and techniques. Chest 80:831-838.
36. McCallion, O.N., Taylor, K.M., Thomas M., et al. 1995. Ultrasonic nebulization of fluids with different viscosity and surface tension. J. Aerosol Med. 8:281-284.
37. Dalby, R.N., Tiano, S.L., and Hickey, A.J. 1996. Medical devices for delivery of therapeutic aerosols to the lungs. In A. Hickey, ed. Inhalation Aerosols, Vol. 94. Marcel Dekker, New York, 441-473.
38. Carpenter, J.F., and Crowe, J.H. 1988. The mechanism of cryoprotection of proteins by solutes cryobiology. Cryobiology 25:244-255.